Superworth4D Molecular Therapeutics price to book ratio FDMT
Market value divided by the book value of the company's net assets, since 2021.
- Today, Oct 23, 2026
- 1.5×
- 6-year median
- 1.6×
- Against its 6-year history
- 46th
- percentile: 0 is its lowest day, 100 its highest
- 6-year range
- 0.2× to 5.4×
- Peer median
- 5.0×
4D Molecular Therapeutics' price to book ratio is 1.5× as of Oct 23, 2026.
That is below its 6-year median of 1.6×, close to the middle of its last 6 years.
Over that time it ranged from 0.2× in Apr 2025 to 5.4× in Mar 2024.
The median for 4 biotech stocks of a similar size is 5.0×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 1.5× | 0.9× | 2.1× |
| 2025 | 1.2× | 0.2× | 1.8× |
| 2024 | 0.5× | 0.5× | 5.4× |
| 2023 | 2.6× | 1.3× | 3.3× |
| 2022 | 2.9× | 0.7× | 3.0× |
| 2021 | 3.1× | 2.5× | 4.2× |
Against its peers
Companies in Biotechnology nearest 4D Molecular Therapeutics' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| FDMT4D Molecular Therapeutics | 1.5× |
| MGTXMeiraGTx | 4.1× |
| PLXProtalix BioTherapeutics | 2.9× |
| VCELVericel | 5.9× |
| ADMAAdma Biologics | 5.9× |
| Peer median | 5.0× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on 4D Molecular Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.